UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it bought in 2023.

UBS Group AG Chief Executive Officer Sergio Ermotti said he will keep cutting headcount in the wake of the historic acquisition of Credit Suisse.

A fifth of private deals in 2024 had some sustainability element, UBS' EMEA president told delegates at the World Economic Forum in Davos on Wednesday.

The defendant was charged after authorities said they discovered that he promised a discount to drivers attending an event at the Elmont venue.

UBS Group AG Chief Executive Officer Sergio Ermotti said he’s looking at whether to follow Wall Street peers in abandoning a key climate-finance alliance, as lenders seek to protect themselves from intensifying political pressure.

And therefore I don't see rates coming down as fast as people believe," Ermotti told CNBC. Freshly inaugurated U.S. President Donald Trump has threatened to impose 25% tariffs on Mexico and Canada, while also floating a separate set of retaliatory trade measures against China.

Chief Executive Officer John McKenzie will present at the 2025 UBS Financial Services Conference on Monday, February 10, 2025, at 8:50 a.m. - 9:30 a.m. ET.Mr. McKenzie will also present at the Bank of America Financial Services Conference on Tuesday,

UBS Group has halted accepting certain bonds and shares of Hong Kong property developer New World Development as collateral for margin loans in recent weeks, Bloomberg News reported on Tuesday. The private banking arms of Citigroup and HSBC Holdings have also stopped lending on New World securities some months ago,

Eric Sim, formerly a managing director at UBS, said people working doggedly towards retirement without knowing what they'll do with their new-found free time will "waste" their days.

UBS raised the firm’s price target on AppLovin (APP) to $440 from $315 and keeps a Buy rating on the shares. The firm has more confidence in

Iovance Biotherapeutics Inc (IOVA) stock saw a modest uptick, ending the day at $5.99 which represents a slight increase of $0.11 or 1.87% from the prior close of $5.88. The stock opened at $5.9 and touched a low of $5.

UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it ...